MedWatch

Biotech-CEO: This is a huge marketing scoop for us

The CEO of a Danish biotech company has struck a deal with two major organizations focusing on cancer immunotherapy, the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute  and the European Association for Cancer Immunotherapy (CIMT).

Foto: Privatfoto

Biotech and diagnostics company Immudex, which was named ‘Entrepreneur of the Year’ within life science in 2011, has just signed a new deal that could prove crucial to the company. It is recognition of the company and a huge scoop, says CEO, Henrik Pedersen.

Immudex develops diagnostic equipment based on its Dextramer technology. The products are aimed at identifying and measuring certain elements of the body’s immune system, such as T cells. A part of the company’s revenue comes from sales of reagents for use in cancer vaccine studies, so-called RUO reagents (Research Use Only).

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier